Selegiline HCL Tablets USP 5mg
Recall D-1479-2016, part of FDA recall event 75025. See Stason Pharmaceuticals's company page.
Stason Pharmaceuticals, Inc. started this Class III drug recall on Aug 23, 2016 (voluntary: firm initiated); FDA lists it as terminated, terminated Oct 23, 2017.
- Classification: Class III
- Started: Aug 23, 2016
- Status: Terminated
Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.
- Product
- Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06
- Quantity
- 17,013 units
- Lots and codes
- Lot #: 14F030, 14F031, 14F032, Exp. June 2017; 15G022, Exp. July 2018
- Distribution
- North Carolina
- Recalling firm
- Stason Pharmaceuticals, Inc., Irvine, CA, United States
- How the firm notified
- Letter
- FDA classified
- Sep 2, 2016
Newest first, one product per recall event; search them all
- Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC…D-0367-2024 · Class III · Feb 9, 2024 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports